8-K: Nektar Reports Q4/FY25 Results, Advances Key Programs

Nektar Therapeutics reported its fourth quarter and full year 2025 financial results, highlighting a strengthened financial position and progress in its clinical pipeline, despite a significant increase in net loss.

Summary

• Cash and investments were $245.8 million as of December 31, 2025, down from $269.1 million on December 31, 2024.
• This cash balance excludes approximately $432 million in net proceeds from a February 2026 secondary offering and $44 million from February/March 2026 at-the-market sales.
• Full year 2025 revenue decreased to $55.2 million from $98.4 million in 2024, primarily due to the sale of the Huntsville manufacturing facility and a decrease in non-cash royalty revenue.
• Full year 2025 net loss increased to $164.1 million, or $9.73 per share, compared to a net loss of $119.0 million, or $8.68 per share, in 2024.
• Research and development (R&D) expense for full year 2025 decreased to $117.3 million from $120.9 million in 2024, mainly due to reduced NKTR-255 development costs, partially offset by increased rezpegaldesleukin development.
• General and administrative (G&A) expense for full year 2025 decreased to $68.7 million from $76.8 million in 2024.
• Successful Phase 2 data readouts for rezpegaldesleukin in atopic dermatitis and alopecia areata were reported, with 52-week data suggesting potential for complete disease clearance.
• A Phase 3 program for rezpegaldesleukin in atopic dermatitis is expected to commence in June 2026.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a mixed report. While the financial results show increased losses and decreased revenue, the successful Phase 2 data for rezpegaldesleukin and the substantial capital raise significantly de-risk the company's ability to advance its lead programs, which is a strong positive for a clinical-stage biotech.

Positives

• Successful and transformative Phase 2 data readouts for rezpegaldesleukin in atopic dermatitis and alopecia areata.
• 52-week treatment data for rezpegaldesleukin provides hope that complete clearance of disease could be possible for patients with monthly and quarterly maintenance dosing.
• Strengthened financial position following a recent public offering that raised $460 million in gross proceeds and $44 million from at-the-market sales.
• Initiation of Phase 3 program for rezpegaldesleukin in atopic dermatitis is planned for June 2026.
• Research collaboration established with UCSF and Dr. Stephen Hauser for NKTR-0165 in multiple sclerosis.
• Full year 2025 R&D expense decreased to $117.3 million from $120.9 million in 2024.
• Full year 2025 G&A expense decreased to $68.7 million from $76.8 million in 2024.

Negatives

• Cash and investments decreased to $245.8 million on December 31, 2025, from $269.1 million on December 31, 2024, prior to recent financing.
• Revenue for the full year 2025 significantly decreased to $55.2 million from $98.4 million in 2024, primarily due to the sale of the Huntsville manufacturing facility and reduced non-cash royalty revenue.
• Net loss for the full year 2025 increased to $164.1 million, or $9.73 per share, compared to a net loss of $119.0 million, or $8.68 per share, in 2024.
• Fourth quarter 2025 saw a net loss of $36.1 million, a significant shift from net income of $7.3 million in the fourth quarter of 2024.
• Non-cash restructuring and impairment charges increased in Q4 2025 to $8.6 million from $1.4 million in Q4 2024, related to the declining San Francisco commercial real estate market.
• Incurred non-cash losses from equity method investment in Gannet BioChem of $8.7 million for the full year 2025.

Risks

• Therapeutic potential of drug candidates (rezpegaldesleukin, NKTR-0165, NKTR-0166, NKTR-422, NKTR-255) is based on preclinical and clinical findings and observations and is subject to change as research and development continue.
• Investigational agents are subject to substantial risks, including negative safety and efficacy findings in future clinical studies, notwithstanding positive findings in earlier preclinical and clinical studies.
• The risk of failure for drug candidates in clinical development is high and can unexpectedly occur at any stage prior to regulatory approval.
• Data reported from ongoing clinical trials are necessarily interim data only, and final results will change based on continuing observations.
• The timing of the commencement or end of clinical trials and the availability of clinical data may be delayed or unsuccessful due to regulatory delays, slower than anticipated patient enrollment, manufacturing challenges, changing standards of care, evolving regulatory requirements, clinical trial design, clinical outcomes, competitive factors, or delay or failure in ultimately obtaining regulatory approval.
• A Fast Track designation does not increase the likelihood that rezpegaldesleukin will receive marketing approval in the United States.
• Patents may not issue from patent applications for drug candidates, patents that have issued may not be enforceable, or additional intellectual property licenses from third parties may be required.
• Certain other important risks and uncertainties are set forth in the Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 7, 2025.

Future Outlook

Nektar Therapeutics anticipates initiating its Phase 3 program for rezpegaldesleukin in atopic dermatitis in June 2026. The company also expects to report topline data from the REZOLVE-AA 16-week treatment extension period in April 2026, and further maintenance data from REZOLVE-AD in the second half of 2026. Preclinical data for the NKTR-0165 program are also slated for presentation in the second half of 2026, with additional long-term data from REZOLVE-AA and REZOLVE-AD, and initial data for rezpegaldesleukin in Type 1 Diabetes, expected in 2027.

Management Comments

• "2025 was a pivotal year for Nektar as we saw successful and transformative Phase 2 data readouts for rezpegaldesleukin."
• "The data highlighted the promise and differentiation of our novel Treg mechanism in two inflammatory dermatological disease settings of atopic dermatitis and alopecia areata."
• "In early 2026, we reported the 52-week treatment data for rezpegaldesleukin. These data provide hope that complete clearance of disease could be possible for patients with monthly and quarterly maintenance dosing of rezpegaldesleukin."
• "With our strengthened financial position following the recent financing, we look forward to initiating our Phase 3 program in atopic dermatitis in June of this year, while we continue to advance our earlier TNFR2 agonist antibody and bispecific program toward the clinic."

Industry Context

StockSavvy.ai notes that Nektar's focus on novel Treg mechanisms for autoimmune and inflammatory diseases positions it in a competitive but high-potential segment of the biopharmaceutical industry. The successful Phase 2 data for rezpegaldesleukin in atopic dermatitis and alopecia areata, coupled with the planned Phase 3 initiation, suggests Nektar is progressing its lead candidate towards commercialization, a critical step for clinical-stage biotech companies. The recent capital raise provides a stronger financial runway, which is crucial for funding expensive late-stage clinical trials and maintaining R&D efforts in a capital-intensive industry.

Comparison to Industry Standards

• The successful Phase 2 data for rezpegaldesleukin in atopic dermatitis and alopecia areata, demonstrating durable and new responses, is a positive indicator, aligning with the typical progression seen in successful drug development programs in the dermatology space. For example, Dupixent (dupilumab) by Regeneron and Sanofi, a leading treatment for atopic dermatitis, also showed strong efficacy in its Phase 2 and 3 trials, leading to its market dominance. While rezpegaldesleukin's mechanism (Treg stimulation) is differentiated, its ability to show "complete clearance of disease" potential at 52 weeks would be highly competitive if replicated in Phase 3, potentially offering a superior or alternative profile to existing biologics like Dupixent or JAK inhibitors (e.g., Rinvoq by AbbVie, Cibinqo by Pfizer).
• The initiation of a Phase 3 program in atopic dermatitis in Q2 2026 is a standard and expected progression for a promising drug candidate following positive Phase 2 results, indicating confidence in the drug's profile and market potential.
• The significant capital raise of $460 million gross proceeds in February 2026 is substantial for a clinical-stage biotech, providing a stronger financial position to fund late-stage trials. This is comparable to capital raises seen by other biotechs advancing into Phase 3, such as those undertaken by companies like Argenx or Incyte during their respective development phases for key assets.

Stakeholder Impact

• Shareholders: Potential for increased value if clinical programs succeed, but dilution from recent capital raise. Strengthened financial position reduces immediate liquidity concerns.
• Patients: Hope for new, effective treatments for atopic dermatitis, alopecia areata, and potentially Type 1 Diabetes based on promising clinical data.
• Employees: Continued employment and R&D activities supported by new funding.
• Creditors: Improved financial stability due to capital raise, potentially reducing credit risk.

Next Steps

• Presentation of REZOLVE-AA 36-week treatment period data at the American Academy of Dermatology (AAD) 2026 Annual Meeting (March 27-31, 2026).
• Reporting of topline data from the blinded 16-week treatment extension period in the Phase 2b REZOLVE-AA study in alopecia areata (April 2026).
• Commencement of Phase 3 studies for rezpegaldesleukin in patients with moderate-to-severe atopic dermatitis (Q2 2026, specifically June).
• Presentation of 36-week maintenance data from the Phase 2b REZOLVE-AD study at a medical conference (second half of 2026).
• Reporting of topline data from the 24-week off-treatment period in REZOLVE-AA (Q4 2026).
• Preclinical data presentation from the NKTR-0165 (TNFR2 agonist antibody) program at a scientific conference (second half of 2026).
• Reporting of topline data from the 52-week off-treatment period in REZOLVE-AD (Q1 2027).
• Reporting of initial data from TrialNet-sponsored Phase 2 study of rezpegaldesleukin in Stage 3 New Onset Type 1 Diabetes (2027).

Key Dates

Recommendation

While Nektar Therapeutics reported a significant increase in net loss and a decrease in revenue for 2025, the successful Phase 2 data for rezpegaldesleukin in multiple indications and the substantial capital raise of over $470 million (net) are critical developments. The financing provides a much-needed runway to advance the lead candidate into Phase 3 trials, which is a major de-risking event for a clinical-stage biotech. However, the company remains unprofitable, and the path to market approval is long and uncertain, with inherent risks in clinical development. The stock is a 'hold' for investors who believe in the long-term potential of rezpegaldesleukin and are comfortable with the high-risk, high-reward nature of biotech investments, especially given the recent financial strengthening to support upcoming milestones.

Keywords

Nektar Therapeutics, NKTR, Biotechnology, Financial Results, Q4 2025, Full Year 2025, Rezpegaldesleukin, Atopic Dermatitis, Alopecia Areata, Phase 2b Study, Phase 3 Program, Clinical Trials, Drug Development, Autoimmune Diseases, Inflammatory Diseases, TNFR2 Agonist, Capital Raise, Public Offering, Biopharma